151851-75-1

Usage

Uses

Used in Pharmaceutical Synthesis:
(R)-2-AMINO-2-ETHYLHEXAN-1-OL is used as a precursor in the pharmaceutical industry for the synthesis of various pharmaceuticals and organic compounds. Its unique structure allows for the creation of a wide range of medications with different therapeutic applications.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, (R)-2-AMINO-2-ETHYLHEXAN-1-OL is utilized for its potential in drug development. Its chiral nature and unique properties make it a promising candidate for the design and synthesis of new drugs with improved efficacy and selectivity.
Used in Chemical Research:
(R)-2-AMINO-2-ETHYLHEXAN-1-OL also finds application in chemical research, where it can be employed to study the effects of chirality on chemical reactions and to develop new methods for the synthesis of enantiomerically pure compounds.

Upstream product

• 152802-65-8 (+/-)-ethyl 2-amino-2-ethylhexanoate 
• 114781-14-5 (R)-2-amino-2-ethylhexanoic acid 

Relevant academic research and scientific papers

PRODUCTION METHOD OF (R)-2-AMINO-2-ETHYLHEXANOL

PROBLEM TO BE SOLVED: To easily and efficiently produce (R)-2-amino-2-ethylhexanol that is useful as a pharmaceutical intermediate without carrying out a complicated operation. SOLUTION: (R)-2-amino-2-ethylhexanol is produced by subjecting a N-benzylidene-2-amino ester derivative to asymmetric alkylation by using an optically active phase transfer catalyst and subsequently subjecting the derivative to removal of benzylidene, reduction and the like. Further the obtained product is made to react with an optically active acid to form a salt to precipitate a solid product. Thus, a solid of the (R)-2-amino-2-ethylhexanol salt is obtained to improve optical purity. COPYRIGHT: (C)2015,JPOandINPIT

Enzymatic- and iridium-catalyzed asymmetric synthesis of a benzothiazepinylphosphonate bile acid transporter inhibitor

A synthesis of the benzothiazepine phosphonic acid 3, employing both enzymatic and transition metal catalysis, is described. The quaternary chiral center of 3 was obtained by resolution of ethyl (2-ethyl)norleucinate (4) with porcine liver esterase (PLE) immobilized on Sepabeads. The resulting (R)-amino acid (5) was converted in two steps to aminosulfate 7, which was used for construction of the benzothiazepine ring. Benzophenone 15, prepared in four steps from trimethylhydroquinone 11, enabled sequential incorporation of phosphorus (Arbuzov chemistry) and sulfur (Pd(0)-catalyzed thiol coupling) leading to mercaptan intermediate 18. S-Alkylation of 18 with aminosulfate 7 followed by cyclodehydration afforded dihydrobenzothiazepine 20. Iridium-catalyzed asymmetric hydrogenation of 20 with the complex of [Ir(COD)2BArF] (26) and Taniaphos ligand P afforded the (3R,5R)-tetrahydrobenzothiazepine 30 following flash chromatography. Oxidation of 30 to sulfone 31 and phosphonate hydrolysis completed the synthesis of 3 in 12 steps and 13% overall yield.

Hypolipidemic 1,4-benzothiazepine derivative

The invention is concerned with a novel hypolipidemic compound, which is of (3R,5R)-3-Butyl-3-ethyl-2,3,4,5-tetrahydro-7-methoxy-5-phenyl-1,4-benzothiazepin-8-ol 1,1-dioxide; or a salt, solvate, or physiologically functional derivative thereof, with processes for its preparation, pharmaceutical compositions containing it and with its use in medicine, particularly in the prophylaxis and treatment of hyperlipidemic conditions, such as athersclerosis.

Hypolipidemic 1,4-benzothiazepine-1,1-dioxides

The invention is concerned with novel hypolipidemic compounds of formula (I), with processes and novel intermedites for their preparation, pharmaceutical compositions containing them and with their use in medicine, particularly in the prophylaxis and treatment of hyperlipidemic conditions, such as atherosclerosis. STR1

Hypolipidaemic condensed 1,4-thiazepines

The invention provides a compound of formula (I), wherein n is an integer of from 0 to 2; R is an optional substituent; R1 is hydrogen or C1-6 alkyl; R2 is an atom or group selected from hydrogen, C1-4 alkyl (including cycloalkyl and cycloalkylalkyl), C1-4 alkoxy, pyrryl, thienyl, pyridyl, 1,3-benzodioxolo, phenyl and naphthyl, which groups are optionally substituted; R3 is hydrogen, OH, C1-6 alkyl, C1-6 alkoxy or --O C1-6 acyl; R4 is a group independently selected from C1-6 alkyl (including cycloalkyl and cycloalkylalkyl), C2-6 alkenyl, and C2-6 -alkynyl which groups are optionally substituted; R5 is a group independently selected from C2-6 alkyl (including cycloalkyl and cycloalkylalkyl), C2-6 alkenyl and C2-6 alkynyl, which groups are optionally substituted; or R4 and R5, together with the carbon atom to which they are attached, form a C3-7 spiro cycloalkyl group which is optionally substituted; R6 and R7 are independently selected from hydrogen and C1-6 alkyl; and X is an aromatic or non-aromatic monocyclic or bicyclic ring system having from 5 to 10 carbon atoms (including the two carbon atoms forming part of the thiazepine ring) wherein optionally one or more of the carbon atoms is/are replaced by heteroatom(s) independently selected from nitrogen, oxygen and sulphur, or X is an aromatic or non-aromatic monocyclic or bicyclic ring system having from 5 to 10 carbon atoms (including the two carbon atoms forming part of the thiazepine ring) wherein one or more of the carbon atoms is/are replaced by heteroatom(s) independently selected from nitrogen, oxygen and sulphur; and salts, solvates and physiologically functional derivatives thereof, pharmaceutical formulations comprising such compounds, processes for their preparation and their use in reducing bile acid uptake and hence as hypolipidaemic compounds. STR1